CHEK1 and triple-negative breast carcinoma: Interestingly, we found that combined enzymatic inhibition of GSK3-β and Chk1 synergizes and triggers apoptosis in triple-negative breast cancer (TNBC) cells, and therefore provides an opportunity to make more effective combination therapy with GSK3-β inhibitors in TNBC and other cancers types.